Trius to Present at the JMP Securities Healthcare Conference

        Print
| Source: Trius Therapeutics, Inc.

SAN DIEGO, July 8, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Tuesday, July 9th at 9:30 a.m. Eastern Time at the JMP Securities Healthcare Conference at the St. Regis Hotel in New York.

A live webcast will be available through the Investor Relations page of the Trius website at http://investor.triusrx.com/events.cfm. A webcast replay will be available approximately two hours after the presentation and will be archived for 30 days.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company's lead investigational drug, tedizolid phosphate, is a novel antibiotic in Phase 3 clinical development for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S., Canada and the European Union. In addition to the Company's tedizolid phosphate clinical program, Trius has initiated Investigational New Drug (IND) enabling studies for its Gyrase-B development candidate with potent activity against Gram-negative bacterial pathogens including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas. For more information, visit www.triusrx.com.

Public Relations Contact:
Laura Kempke/Stacey Holifield at MSLGROUP

781-684-0770

Investor Relations Contact:
Stefan Loren at Westwicke Partners, LLC

443-213-0507